Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Locally Advanced HER2-positive Breast Cancer

Next Previous
Trial Profile

A Phase II Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Locally Advanced HER2-positive Breast Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anbenitamab (Primary) ; Fulvestrant (Primary) ; Palbociclib (Primary)
  • Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Alphamab Oncology

Most Recent Events

  • 14 Jul 2023 Status changed from recruiting to discontinued since difficulty in completing enrollment within the planned time.
  • 31 May 2022 Planned number of patients changed from 66 to 36.
  • 31 May 2022 Planned End Date changed from 15 Apr 2022 to 30 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top